Harmony Biosciences Holdings, Inc. (HRMY) - Q1 2026 Filing Summary
Business Context and Reporting Period
This summary covers the Quarterly Report on Form 10-Q for Harmony Biosciences Holdings, Inc. for the period ended March 31, 2026. Harmony is a neuroscience company focused on rare neurological diseases, primarily commercializing WAKIX (pitolisant) for narcolepsy. The company operates a single reportable segment and is headquartered in Plymouth Meeting, Pennsylvania.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Net Product Revenue | $215.4 million | $184.7 million |
| Gross Profit | $170.9 million | $152.7 million |
| Operating Income | $37.3 million | $56.2 million |
| Net Income | $32.5 million | $45.6 million |
| Diluted EPS | $0.55 | $0.78 |
| Cash & Investments | $870.5 million | $489.3 million (End of Q1 2025) |
| Long-Term Debt (Principal) | $160.0 million | $165.0 million |
| Operating Cash Flow | $27.8 million | $34.0 million |
Material Changes vs. Prior Period
- Revenue Growth: Net product revenue increased 16.6% year-over-year, driven by a 12.1% increase in units shipped and a 7% price increase implemented in January 2026, partially offset by higher rebates.
- Profitability Decline: Net income decreased 28.7% to $32.5 million. This was primarily due to a $32.0 million non-cash in-process research and development (IPR&D) charge related to upfront license fees for new agreements (Novitium and MSN).
- Expense Increases: Research and Development (R&D) expenses doubled to $69.4 million, largely due to the $32.0 million IPR&D charge and increased clinical trial costs for EPX-100 and Pitolisant GR/HD. Cost of Product Sold increased 39.1% due to higher royalties tied to revenue growth.
- Investing Activity: Net cash used in investing activities was $183.6 million, driven by $179.0 million in purchases of investment securities and $32.0 million in upfront license fees.
Guidance, Outlook, and Risks
- Pipeline Progress:
- WAKIX: FDA approved for cataplexy in pediatric patients (6+ years) in February 2026. The company is pursuing pediatric exclusivity.
- Pitolisant GR: Bioequivalence data readout in Q4 2025 supports NDA submission in Q2 2026.
- EPX-100 (Epygenix): Phase 3 trials for Dravet Syndrome and Lennox-Gastaut Syndrome are ongoing; topline data expected in 2027.
- BP-205: First-in-human studies initiated in Q4 2025; US IND planned for mid-2026.
- Liquidity: Management believes existing cash and investments ($870.5 million) are sufficient to fund operations for at least the next 12 months.
- Debt Covenant Waiver: The company had an event of default regarding a nonfinancial covenant (subsidiary guarantor delay) as of March 31, 2026. A waiver was obtained on May 4, 2026, and the company is currently in compliance.
- Legal Proceedings: Multiple ANDA (generic) litigation cases regarding WAKIX have been settled with Lupin, Novugen, Novitium, Hikma, Annora, and MSN, generally allowing generic entry in 2030 subject to pediatric exclusivity. A new lawsuit was filed in April 2026 against AET Pharma and Sandoz.
Investor Verification Checklist
- IPR&D Charges: Verify the strategic value and future milestone obligations associated with the $32.0 million upfront license fees paid to Novitium and MSN in Q1 2026.
- Debt Covenant Status: Confirm the long-term stability of the credit facility following the recent waiver of the covenant default.
- Generic Competition Timeline: Monitor the status of pediatric exclusivity for WAKIX, which determines the 2030 generic entry date agreed upon in recent settlements.
- Revenue Mix: Assess the sustainability of the 7% price increase and the impact of rising rebate rates on gross margins.
- Cash Burn vs. Investment: Evaluate the balance between the significant cash outflow for investments ($179M) and license fees against the company's runway for clinical trials.